Last reviewed · How we verify
NCT05906615: LIDOPAN
Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis
Phase 2 trial testing Lidocaine IV in Pancreatic Cancer in 30 participants. Completed in 1 July 2023.
1 July 2023
Quick facts
| Lead sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 14 January 2021 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 July 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Lidocaine IV — full drug profile →
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Chronic Pancreatitis — all drugs for Chronic Pancreatitis →
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →
Who can join
18 and older, any sex, with Pancreatic Cancer or Chronic Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pain is a major clinical problem for many patients with pancreatic cancer and chronic pancreatitis (CP).In pancreatic cancer, nearly 75% of patients suffer from pain at the time of diagnosis, with over 90% of patients in advanced stages. In CP, pain occurs in 80-90% of patients and strongly affects quality of life. For both conditions, the majority of pain is addressed using the WHO analgesic ladder. However, more invasive pain therapies are often necessary. Currently, in several centers in the Netherlands, treatment with IV lidocaine is already used in clinical practice in patients with pancreatic cancer and CP. Based on practical experience, the majority of patients benefit from this therapy, however, its efficacy in terms of duration of pain relief, decrease in pain scores, increase in patient satisfaction and adverse events is unknown. Therefore, the aim of this study is to investigate the efficacy of monitored single intravenous infusion in patients with pancreatic cancer and CP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05906615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lidocaine IV
Trials testing the same drug.
- NCT05788393 — Opioid Sparing Analgesia Continuous Intraoperative Infusion of Dexmedetomidine Versus Lidocaine for Laparoscopic Cholecy · Phase 4 · completed
- NCT06243120 — Intravenous Lidocaine for Treating Intrathecal Fentanyl Induced Pruritus · EARLY_PHASE1 · unknown
- NCT06423456 — Postoperative Pain Control Following Hysteroscopy · NA · completed
- NCT06516861 — Magnesium Sulphate and Lidocaine in Hemodynamic Changes and Cortisol Levels · Phase 1 · completed
- NCT06433713 — Effect of Intraoperative Intravenous Lidocaine on Postoperative Pain and Return of Bowel Function After Cesarean Section · Phase 2 · completed
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials
Trials by the same sponsor.
- NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
- NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
- NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
- NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05906615 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Last refreshed: 2 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05906615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing